#GLP-1 class

Coverage of the GLP-1 receptor agonist family and its successors.

A post hoc SURMOUNT-1 analysis found limited regain was common during continued tirzepatide treatment, but selection limits matter.

A 2026 review proposes phenotype-enriched testing of GLP-1 drugs in ADPKD, but direct semaglutide evidence remains preclinical.

A matched CKD cohort linked GLP-1 receptor agonist use with less atrial fibrillation, but the retrospective design cannot prove prevention.

A multi-method preclinical study linked SIRT1 loss to CKD-related valve calcification and found a semaglutide signal in cells and mice.

A 2026 review links obesity treatment with better sleep-apnea measures. We separate its conclusions from the randomized tirzepatide evidence.

A 2026 review links GLP-1 drugs to possible ocular-surface repair and changes around the eye, but human evidence remains small and observational.

A five-year database study linked GLP-1 drugs to fewer lung complications in people with sleep apnea and type 2 diabetes, without proving causation.

A matched US database study links GLP-1 drug use in sleep apnea with fewer strokes, hospital visits and deaths, but it cannot prove cause and effect.

A 2026 systematic review links pediatric GLP-1 medicines with lower BMI or HbA1c, while highlighting gastrointestinal effects and long-term gaps.

A human stem-cell study links tirzepatide to faster pacemaker-cell beating through cAMP and calcium signalling, but it is not a patient trial.

Two case reports link GLP-1 medicines to unusual skin reactions. Here is what they observed, and why they cannot establish risk or causation.

Tirzepatide weight loss includes fat and lean mass changes. Here is what body composition research can, and cannot, tell you.